Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nonmyeloablative Conditioning with Fludarabine and TBI for CML
NCT00110058Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Feb 2005
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine in chronic myeloid leukemia (CML), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Progression-free survival and Disease-free survival rate. Started Feb 2005; status: completed.
02
Drugs
fludarabine
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00110058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00110058.